Regeneron Pharmaceuticals Inc. (REGN)
NASDAQ: REGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
REGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $76.40B
- P/E (TTM)
- 18.35
- Forward P/E
- 12.07
- EPS (TTM)
- $40.44
- Dividend yield
- 0.49% ($3.64)
- Ex-dividend date
- Aug 18, 2026
- 52-week range
- 541.00 – 859.34
- Day range
- 734.18 – 753.66
- Volume / Avg
- 626.38K / 741.47K
- Beta
- —
- Shares outstanding
- 101.14M
- Next earnings
- Oct 30, 2026
52-week range
REGN stock today
On Oct 7, REGN ended the session at $742.12, adding $3.40 (0.46%), versus the S&P 500's 0.22% decline. At this level, REGN sits in the middle of its 52-week range of $541.00 to $859.34: 13.6% below the high, set on Sep 3, 2026 and 37.2% above the low. REGN is down 3.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 27.2%.
At 18.4x trailing earnings, Regeneron Pharmaceuticals trades below the peer-group median of 30.2x. Its forward P/E of 12.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Regeneron Pharmaceuticals's next earnings report is expected on Oct 30, 2026. Regeneron Pharmaceuticals pays an annual dividend of $3.64 per share, a 0.49% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Regeneron Pharmaceuticals
Company profileRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Leonard S. Schleifer M.D., Ph.D.
- Headquarters
- Tarrytown, NY
- Employees
- 15,410
- IPO year
- 1991
- Website
- regeneron.com
Financial highlights
Full financialsIn fiscal 2025, Regeneron Pharmaceuticals generated $14.34 billion in revenue, up 1.0% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $4.50 billion (+2.1% year over year), for a net margin of 31.4% versus a median of 35.6% in the prior 5 years. Operating margin was 24.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| Growth | +0.99% | +8.27% | +7.76% | -24.26% | +89.14% |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| EPS (diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
Analyst forecast
ForecastConsensus (27 analysts)
buy
Avg. price target
$856.23+15.38%
- Strong buy 4
- Buy 14
- Hold 8
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 30, 2026
- EPS estimate
- $13.51
- Last reported (Q2 2026)
- Jul 30, 2026
- EPS actual vs est.
- $12.23 vs —
Dividends
Dividend history- Annual dividend
- $3.64
- Dividend yield
- 0.49%
- Last payment
- $0.94
- Ex-dividend date
- Aug 18, 2026
REGN news
All REGN news- Repligen Corp Completes Acquisition Of BioLife SolutionsNasdaqREGN, RGEN
- Regeneron sees nearly $0.18 per share earnings headwind in Q3Seeking Alpha
- Regeneron: The Easy Money Has Been Made (Rating Downgrade)Seeking Alpha
- iShares Biotechnology ETF Experiences Big InflowNasdaqIBB, REGN, NTRA, ARGX
- Sanofi, Regeneron Expand Immunology Alliance With New AntibodiesNasdaqREGN, SNY, AZN
- Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies TranscriptSeeking Alpha
- Regeneron's Ubamatamab, Trevogrumab Show Strong Results In Cancer And Obesity StudiesNasdaq
- Argus Research Upgrades Regeneron Pharmaceuticals to Buy from HoldNasdaq
Regeneron Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TAKTakeda Pharmaceutical Company Limited ADR | 18.37 | +1.49% | $58.68B | vs REGN |
| GSKGSK plc ADR | 47.02 | +0.90% | $94.21B | vs REGN |
| SNYSanofi ADS | 40.20 | +1.62% | $96.32B | vs REGN |
| TEVATeva Pharmaceutical Industries Limited | 39.18 | +0.13% | $45.70B | vs REGN |
| ONCBeOne Medicines Ltd. ADR | 364.02 | +0.34% | $41.41B | vs REGN |
| RPRXRoyalty Pharma plc Class A | 56.76 | +0.57% | $32.80B | vs REGN |
| BMYBristol-Myers Squibb Company | 59.70 | +0.18% | $121.95B | vs REGN |
| ALNYAlnylam Pharmaceuticals Inc. | 224.41 | +0.21% | $30.03B | vs REGN |
Indexes, lists and sector
Index membership
Appears in lists
Regeneron Pharmaceuticals stock FAQ
What is Regeneron Pharmaceuticals's stock price today?
REGN last traded at $742.12 as of Oct 7, 4:00 PM EDT, up 0.46% on the day. Prices are delayed at least 15 minutes.
Does Regeneron Pharmaceuticals pay a dividend?
Yes. Regeneron Pharmaceuticals pays $3.64 per share annually, a 0.49% yield. The most recent dividend of $0.94 had an ex-dividend date of Aug 18, 2026.
When is Regeneron Pharmaceuticals's next earnings date?
Regeneron Pharmaceuticals is expected to report earnings on Friday, October 30, 2026. Analysts expect EPS of $13.51.
What is REGN's P/E ratio?
REGN trades at a trailing P/E ratio of 18.35 and a forward P/E of 12.07, compared with a median of 30.2 for its closest peers.
Is Regeneron Pharmaceuticals in the S&P 500?
Yes. Regeneron Pharmaceuticals (REGN) is a constituent of the S&P 500 index.
Who is Regeneron Pharmaceuticals's CEO?
Dr. Leonard S. Schleifer M.D., Ph.D. is the chief executive officer of Regeneron Pharmaceuticals Inc., which has about 15,410 employees.
What is the REGN 52-week high?
The 52-week high for REGN is $859.34 and the 52-week low is $541.00. The stock is currently 13.6% below its high.